Small molecule inhibition rescues the skeletal dysplasia phenotype of Trpv4 mutant mice

Area of Science:

• Genetics and Molecular Biology
• Skeletal Biology
• Pharmacology

Background:

• TRPV4 skeletal dysplasias are genetic disorders characterized by short stature, limb shortening, and scoliosis.
• These conditions arise from activating mutations in the TRPV4 gene, affecting a calcium-permeable ion channel crucial for skeletal development.
• Understanding the disease mechanisms and exploring therapeutic interventions are critical for managing these debilitating conditions.

Purpose of the Study:

• To develop a mouse model for studying TRPV4 skeletal dysplasias and testing therapeutic strategies.
• To investigate the efficacy of TRPV4 channel inhibition as a treatment for these disorders.
• To elucidate the molecular mechanisms underlying skeletal defects in TRPV4-associated conditions.

Main Methods:

• Generation of a knock-in mouse model with a conditional p.R594H Trpv4 mutation, induced specifically in chondrocytes using Col2a1-Cre.
• Histological analysis of cartilage growth plates to assess endochondral ossification.
• In vivo administration of a TRPV4-specific inhibitor (GSK2798745) to evaluate therapeutic effects.
• Single-cell RNA sequencing (scRNA-Seq) of chondrocyte transcripts to identify molecular pathways involved in the disease.

Main Results:

• The conditional Trpv4 mutation in mice recapitulated key skeletal dysplasia phenotypes observed in human patients, including long bone, spine, and craniofacial abnormalities.
• Histological examination revealed disorganized chondrocyte columns and impaired hypertrophic chondrocyte development in the growth plates of affected mice.
• Treatment with the TRPV4 inhibitor GSK2798745 significantly improved radiographic skeletal features and rescued growth plate abnormalities.
• scRNA-Seq analysis identified calcium-mediated signaling pathway dysregulation contributing to growth defects.

Conclusions:

• The developed mouse model effectively mimics TRPV4 skeletal dysplasias, providing a valuable platform for disease research.
• TRPV4 channel inhibition demonstrates significant therapeutic potential, improving skeletal phenotypes and histological defects in the mouse model.
• Calcium-mediated signaling pathways are implicated in the pathogenesis of TRPV4 skeletal dysplasias, highlighting potential therapeutic targets.